Affymax Inc: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Affymax is a biopharmaceutical company creating novel approaches for the treatment of kidney disease and cancer. It seeks to build a franchise of products through its own internal efforts as well as partnering with other pharmaceutical companies such as Takeda and EntreMed. The company's most advanced product candidate Hematide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA).


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Affymax's product focus is in the development of synthetic peptide-based drug candidates. The company has developed a discovery platform based on advanced recombinant peptide and peptide chemistry techniques that allows it to generate novel peptide alternatives to protein drugs.

    Affymax derives its revenues from collaboration and licensing agreements. These revenues are related mainly to the two separate collaboration agreements with Takeda for the development and commercialization of Hematide. During the period 2002-2006, the company's total revenues increased from $0.1 million in 2002 to $12 million in 2006.

    Affymax's major contributor to sales growth out to 2010 will be the royalties, license and collaboration revenues. Revenues from this stream are expected to contribute absolute sales growth of +$100 million during the period 2006-2010. The absolute increase from this revenue stream is expected primarily due to the revenues earned in


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: affymax hematide tracy peter forecast young drug dunn purchase peptide

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.